top of page
1_edited_edited.jpg

Notice of Patent License Agreement for a Novel CAR T-Cell Therapy Targeting GD2 Antigen


January 13, 2024

T Celll Nouveau Inc.


Notice of Patent License Agreement for a

Novel CAR T-Cell Therapy Targeting GD2 Antigen



T Cell Nouveau Inc. (Headquartered in Chuo-ku, Tokyo and represented by Chairman and Representative Director, Kazuto Takesako, hereinafter referred to as the “Company”) has concluded a License Agreement (hereinafter, the 'License Agreement') with Mie University (National University Corporation, headquartered in Tsu, Mie and represented by President Masaaki Ito, hereinafter "Mie University") for the patents mentioned above (hereinafter referred to as the "License Agreement").


CAR-T cell therapy has shown groundbreaking efficacy in the treatment of leukemia and malignant lymphoma. This immunotherapy was pioneered by Kymria® with first Japan domestic approval in 2019. However, achieving similar results for solid tumors requires further advancement. To address this challenge, The Company has collaborated with the Mie University Graduate School of Medicine, Department of Personalized Cancer Immunotherapy to jointly develop T-cell therapy. Furthermore we have concluded a license agreement concerning CAR-T cell therapy targeting GD2 glycolipid.  This step aims to expedite clinical application of T-cell therapy for solid tumors and advance regenerative medicine.


(Reference)

About GD2:

GD2 is a glycolipid predominantly expressed on the surface of nerve cells, confirmed to be excessively expressed in various cancers, including neuroblastoma, a type of pediatric cancer, as well as tripple negative breast cancer and melanoma.

Comentarios


bottom of page